Logo image of SMFR

SEMA4 HOLDINGS CORP (SMFR) Stock Fundamental Analysis

NASDAQ:SMFR - Nasdaq - US81663L1017 - Common Stock - Currency: USD

0.3106  +0.07 (+26.78%)

After market: 0.32 +0.01 (+3.03%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to SMFR. SMFR was compared to 108 industry peers in the Health Care Providers & Services industry. SMFR has a bad profitability rating. Also its financial health evaluation is rather negative. SMFR is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year SMFR has reported negative net income.
SMFR had a negative operating cash flow in the past year.
SMFR Yearly Net Income VS EBIT VS OCF VS FCFSMFR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 -100M -200M -300M -400M

1.2 Ratios

SMFR has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SMFR Yearly ROA, ROE, ROICSMFR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 -1K -2K -3K -4K -5K

1.3 Margins

SMFR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SMFR Yearly Profit, Operating, Gross MarginsSMFR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 0 -50 -100 -150 -200

More info and screens

3

2. Health

2.1 Basic Checks

SMFR does not have a ROIC to compare to the WACC, probably because it is not profitable.
SMFR has more shares outstanding than it did 1 year ago.
The debt/assets ratio for SMFR has been reduced compared to a year ago.
SMFR Yearly Shares OutstandingSMFR Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 50M 100M 150M 200M
SMFR Yearly Total Debt VS Total AssetsSMFR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 100M 200M 300M 400M 500M

2.2 Solvency

Based on the Altman-Z score of -2.45, we must say that SMFR is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of SMFR (-2.45) is worse than 80.00% of its industry peers.
A Debt/Equity ratio of 0.10 indicates that SMFR is not too dependend on debt financing.
With a decent Debt to Equity ratio value of 0.10, SMFR is doing good in the industry, outperforming 78.26% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF N/A
Altman-Z -2.45
ROIC/WACCN/A
WACC8.77%
SMFR Yearly LT Debt VS Equity VS FCFSMFR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 0 100M -100M 200M -200M 300M

2.3 Liquidity

SMFR has a Current Ratio of 1.89. This is a normal value and indicates that SMFR is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.89, SMFR is in the better half of the industry, outperforming 73.91% of the companies in the same industry.
SMFR has a Quick Ratio of 1.62. This is a normal value and indicates that SMFR is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of SMFR (1.62) is better than 68.70% of its industry peers.
Industry RankSector Rank
Current Ratio 1.89
Quick Ratio 1.62
SMFR Yearly Current Assets VS Current LiabilitesSMFR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 100M 200M 300M 400M

More info and screens

6

3. Growth

3.1 Past

SMFR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 32.61%, which is quite impressive.
SMFR shows a small growth in Revenue. In the last year, the Revenue has grown by 5.79%.
SMFR shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 16.75% yearly.
EPS 1Y (TTM)32.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53.49%
Revenue 1Y (TTM)5.79%
Revenue growth 3Y16.75%
Revenue growth 5YN/A
Sales Q2Q%92.77%

3.2 Future

Based on estimates for the next years, SMFR will show a quite strong growth in Earnings Per Share. The EPS will grow by 8.27% on average per year.
The Revenue is expected to grow by 22.80% on average over the next years. This is a very strong growth
EPS Next Y14.52%
EPS Next 2Y26.72%
EPS Next 3Y20.59%
EPS Next 5Y8.27%
Revenue Next Year19.89%
Revenue Next 2Y3.4%
Revenue Next 3Y7.95%
Revenue Next 5Y22.8%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
SMFR Yearly Revenue VS EstimatesSMFR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 100M 200M 300M 400M 500M
SMFR Yearly EPS VS EstimatesSMFR Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

SMFR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year SMFR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SMFR Price Earnings VS Forward Price EarningsSMFR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SMFR Per share dataSMFR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

SMFR's earnings are expected to grow with 20.59% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.72%
EPS Next 3Y20.59%

More info and screens

0

5. Dividend

5.1 Amount

SMFR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SEMA4 HOLDINGS CORP

NASDAQ:SMFR (1/9/2023, 8:00:03 PM)

After market: 0.32 +0.01 (+3.03%)

0.3106

+0.07 (+26.78%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-14 2022-11-14/bmo
Earnings (Next)03-13 2023-03-13
Inst Owners0.03%
Inst Owner Change0%
Ins Owners0.24%
Ins Owner Change0%
Market Cap118.47M
Analysts80
Price Target1.79 (476.3%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-4.49%
Min EPS beat(2)-16.71%
Max EPS beat(2)7.73%
EPS beat(4)3
Avg EPS beat(4)6.97%
Min EPS beat(4)-16.71%
Max EPS beat(4)35.32%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-16.82%
Min Revenue beat(2)-47.5%
Max Revenue beat(2)13.86%
Revenue beat(4)2
Avg Revenue beat(4)-4.89%
Min Revenue beat(4)-47.5%
Max Revenue beat(4)14.12%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-22.22%
PT rev (3m)N/A
EPS NQ rev (1m)23.81%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.51
P/FCF N/A
P/OCF N/A
P/B 0.21
P/tB 0.62
EV/EBITDA N/A
EPS(TTM)-0.93
EYN/A
EPS(NY)-0.48
Fwd EYN/A
FCF(TTM)-0.85
FCFYN/A
OCF(TTM)-0.8
OCFYN/A
SpS0.61
BVpS1.47
TBVpS0.5
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.28
Health
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 61.73%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.89
Quick Ratio 1.62
Altman-Z -2.45
F-Score1
WACC8.77%
ROIC/WACCN/A
Cap/Depr(3y)203.02%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)32.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53.49%
EPS Next Y14.52%
EPS Next 2Y26.72%
EPS Next 3Y20.59%
EPS Next 5Y8.27%
Revenue 1Y (TTM)5.79%
Revenue growth 3Y16.75%
Revenue growth 5YN/A
Sales Q2Q%92.77%
Revenue Next Year19.89%
Revenue Next 2Y3.4%
Revenue Next 3Y7.95%
Revenue Next 5Y22.8%
EBIT growth 1Y-0.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year23.4%
EBIT Next 3Y20.26%
EBIT Next 5Y6.72%
FCF growth 1Y-68.84%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-104.49%
OCF growth 3YN/A
OCF growth 5YN/A